A Study of Cell Therapy for Subjects With Acute Kidney Injury Who Are Receiving Continuous Renal Replacement Therapy

Inclusion Criteria: * AKI, as determined by the Investigator based on his/her clinical judgment * Able to tolerate indwelling intravascular access * Has tolerated Continuous Renal Replacement Therapy for at least 12 hours prior to IP treatment * Likely to require Continuous Renal Replacement Therapy for at least an additional 48 hours * Ability to give informed consent Exclusion Criteria: * Female subjects who are pregnant, planning to become pregnant, or lactating * Known end-stage liver disease * Hepatorenal syndrome * Acute glomerulonephritis (e.g. rapidly progressive glomerulonephritis; membranoproliferative glomerulonephritis; post-streptococcal glomerulonephritis); acute interstitial nephritis (e.g. toxin- or drug- induced interstitial nephritis) or hereditary renal disease (e.g. Alport's Syndrome; polycystic kidney disease) * AKI due to post-renal outflow obstruction * Acute or chronic vasculitis of any etiology * At the time of randomization, clinical evidence (e.g. febrile) suggestive of an uncontrolled or inadequately treated systemic infection * History of a chronic systemic infection of any etiology regardless of therapy * Active malignancy(-ies) and/or receiving active treatment for a malignancy(-ies), with the exception of non-melanoma skin cancer * Subjects, who in the opinion of the Investigator, are likely to require escalating doses of vasopressors to attain and/or maintain hemodynamic stability * Systemic immunosuppressive therapy that has not been stabilized for greater than 4 months, or in the case of chronic corticosteroid therapy, a dose of \>15 mg/day of prednisone or the equivalent within the past 30 days * Organ failure affecting more than 2 non-renal organs * Platelet count \<25,000/uL or other serious hematological abnormalities that would place subject in imminent danger of death * Any prior medical condition that, in the judgment of the Investigator, would prevent the subject from safely participating in and/or completing all study requirements